Stay up to date with the latest news from Cisterna, from new product launches and partnerships to milestones and what we're building next.
Cisterna Biologics has successfully completed its NSF SBIR Phase I project, demonstrating for the first time that yeast-engineered mRNA can be selectively purified and drive protein expression in human cells, laying the groundwork for a more scalable, cost-efficient approach to non-immunogenic mRNA manufacturing.
